View More Recent Stories
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
Nurix Therapeutics (NRIX) Receives FDA Fast Track Designation for NX-5948
-
Nurix (NRIX) PT Raised to $35 at H.C. Wainwright
-
BMO Capital Starts Nurix (NRIX) at Outperform
-
Nurix Therapeutics (NRIX) Receives PRIME Designation from the European Medicines Agency for NX-5948
-
UBS Starts Nurix (NRIX) at Buy
-
Nurix (NRIX) PT Raised to $30 at H.C. Wainwright
-
Nurix Therapeutics (NRIX) Appoints Anil Kapur to its Board
-
Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
-
Nurix (NRIX) PT Raised to $34 at Stifel
-
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
-
Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
-
Jefferies Starts Nurix (NRIX) at Buy
-
Truist Securities Reiterates Buy Rating on Nurix (NRIX)
-
Baird Assumes Nurix (NRIX) at Outperform
-
Nurix (NRIX) PT Raised to $27 at Oppenheimer
-
Truist Securities Starts Nurix (NRIX) at Buy
-
Nurix (NRIX) PT Raised to $30 at Stifel
-
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
-
Nurix (NRIX) PT Lowered to $29 at Needham
-
Nurix (NRIX) PT Raised to $27 at RBC Capital
-
Nurix Therapeutics, Inc. (NRIX) Misses Q2 EPS by 8c
-
Nurix (NRIX) PT Raised to $26 at RBC Capital
-
Nurix (NRIX) PT Raised to $26 at H.C. Wainwright
-
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
-
RBC Capital Reiterates Outperform Rating on Nurix (NRIX)

